Xenetic Biosciences is trading at $2.09, down 6.68% in pre-market; biotech weakness offers context but does not establish the full cause. - The XBI ETF was down 2.01% pre-market amid negative company-specific developments elsewhere in biotech. - No new company announcement surfaced for October 2; the latest listed release was the September 16 Santersus share-exchange announcement. - That transaction is prior news and is not clearly linked to the overnight decline.